While interleukin-1beta (IL-1beta) is a potent pro-inflammatory cytokine essential for host defense, high systemic levels cause life-threatening inflammatory syndromes. ATP, a stimulus of IL-1beta maturation, is released from damaged cells along with beta-nicotinamide adenine dinucleotide (beta-NAD). Here, we tested the hypothesis that beta-NAD controls ATP-signaling and, hence, IL-1beta release. Lipopolysaccharide-primed monocytic U937 cells and primary human mononuclear leukocytes were stimulated with 2'(3')-O-(4-benzoyl-benzoyl)ATP trieethylammonium salt (BzATP), a P2X7 receptor agonist, in the presence or absence of beta-NAD. IL-1beta was measured in cell culture supernatants. The roles of P2Y receptors, nicotinic acetylcholine receptors (nAChRs), and Ca(2+)-independent phospholipase A2 (iPLA2beta, PLA2G6) were investigated using specific inhibitors and gene-silencing. Exogenous beta-NAD signaled via P2Y receptors and dose-dependently (IC50 = 15 microM) suppressed the BzATP-induced IL-1beta release. Signaling involved iPLA2beta, release of a soluble mediator, and nAChR subunit alpha9. Patch-clamp experiments revealed that beta-NAD inhibited BzATP-induced ion currents. In conclusion, we describe a novel triple membrane-passing signaling cascade triggered by extracellular beta-NAD that suppresses ATP-induced release of IL-1beta by monocytic cells. This cascade links activation of P2Y receptors to non-canonical metabotropic functions of nAChRs that inhibit P2X7 receptor function. The biomedical relevance of this mechanism might be the control of trauma-associated systemic inflammation.
- Hiller, S. D.
- Heldmann, S.
- Richter, K.
- Jurastow, I.
- Kullmar, M.
- Hecker, A.
- Wilker, S.
- Fuchs-Moll, G.
- Manzini, I.
- Schmalzing, G.
- Kummer, W.
- Padberg, W.
- McIntosh, J. M.
- Damm, J.
- Zakrzewicz, A.
- Grau, V.
Keywords
- Adenosine Triphosphate/metabolism
- Cell Line, Tumor
- Cells, Cultured
- Humans
- Interleukin-1beta/*metabolism
- Lipopolysaccharides/pharmacology
- Monocytes/*metabolism
- NAD/*pharmacology
- Nicotinic Antagonists/pharmacology
- Phospholipase A2 Inhibitors/pharmacology
- Phospholipases A2/genetics/metabolism
- Purinergic P2Y Receptor Antagonists/pharmacology
- Receptors, Nicotinic/genetics/metabolism
- Receptors, Purinergic P2Y/genetics/metabolism
- Chrna10
- Chrna7
- Chrna9
- P2ry1
- P2ry11
- Pla2g6
- U937 cells
- iPLA2beta
- inflammasome
- interleukin-1beta
- monocyte
- beta-NAD
- beta-nicotinamide adenine dinucleotide
- antagonists used in this study. All other authors declare no conflict of
- interest.